This filing announces Huron Consulting Group's inclusion in the S&P SmallCap 600 index, effective November 2, 2026, replacing Supernus Pharmaceuticals. This move is primarily a technical adjustment that can lead to increased passive fund buying for HURN and selling for SUPN.
Huron Consulting Group (HURN) is being added to the S&P SmallCap 600 index, while Supernus Pharmaceuticals (SUPN) is being removed. This is a significant event for both companies as index inclusion often leads to increased demand from passive funds that track the index, potentially boosting HURN's stock price. Conversely, SUPN may experience selling pressure as these funds rebalance their portfolios. The long-term implications for HURN could include improved liquidity and investor visibility, while SUPN might face reduced institutional interest. For traders, the key opportunity lies in anticipating the rebalancing act by index-tracking funds, especially closer to the effective date of November 2, 2026.